Last reviewed 2026-05-22 · How we verify

Clofluonide (LOFLUCARBAN)

Phase 2 active Small molecule ✓ Verified May 2026

Clofluonide (generic name: LOFLUCARBAN) is a loflucarban drug. It is currently in Phase 2 development.

Clofluonide works by inhibiting a specific enzyme or receptor, although the exact target is unknown.

Clofluonide, also known as Loflucarban, is a small molecule drug in the loflucarban class. Its original development is unclear, and its current owner is also unknown. The target of Clofluonide is not specified, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety considerations. Further research is needed to determine the potential uses and risks of this compound.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LOFLUCARBAN
Drug class	loflucarban
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and the key to opening those locks is a specific molecule. Clofluonide is like a fake key that blocks the real key from fitting, preventing the cell from doing something it's supposed to do. This can help treat certain conditions by reducing the activity of the cell.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clofluonide CI brief — competitive landscape report
Clofluonide updates RSS · CI watch RSS

Frequently asked questions about Clofluonide

What is Clofluonide?

Clofluonide (LOFLUCARBAN) is a loflucarban drug.

How does Clofluonide work?

Clofluonide works by inhibiting a specific enzyme or receptor, although the exact target is unknown.

What is the generic name of Clofluonide?

LOFLUCARBAN is the generic (nonproprietary) name of Clofluonide.

What drug class is Clofluonide in?

Clofluonide belongs to the loflucarban class. See all loflucarban drugs at /class/loflucarban.

What development phase is Clofluonide in?

Clofluonide is in Phase 2.

Drug class: All loflucarban drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing